
Novavax (NVAX) Stock Forecast & Price Target
Novavax (NVAX) Analyst Ratings
Bulls say
Novavax is a promising biotechnology company with a strong focus on developing novel vaccines for a wide range of diseases. Their Matrix-M adjuvant seems to be a key value driver, as it has shown great potential in their COVID vaccine trials and could potentially be used in other pipeline programs as well. With multiple partnerships and collaborations in place, Novavax has a strong foundation for future success and growth in the vaccines market.
Bears say
Novavax is facing several challenges that could impact its financial performance in the future. These include the limited market share for its COVID-19 vaccine Nuvaxovid among older adults, the expected decline in flu vaccination rates for those aged 50-64, and the potential competition from other companies in the flu market. Additionally, the company's partnership with Sanofi may not yield significant revenue, and the risks associated with successful development and increased vaccination rates may not materialize. This could result in lower-than-expected revenues and negatively affect the company's stock performance.
This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.
Novavax (NVAX) Analyst Forecast & Price Prediction
Start investing in Novavax (NVAX)
Order type
Buy in
Order amount
Est. shares
0 shares